Shilpa Medicare Limited – FDA 483
The FDA inspection of Shilpa Medicare Limited revealed significant deficiencies across multiple areas, including a failing Quality Unit that inadequately classified complaints and OOS results, and a lack of effective CAPAs. The firm demonstrated poor control over sterile and non-sterile drug product manufacturing, with issues in process validation, aseptic processing, environmental monitoring, and laboratory controls. Additionally, the company failed to maintain proper instrument calibration, ensure data integrity, manage reserve samples correctly, and submit timely Field Alert Reports, indicating systemic quality and compliance breakdowns.
- Company
- Shilpa Medicare Limited
- Product type
- drugs
ID · 1533339e-2565-4102-a4c6-10f007e2112a
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.